E-Nitiate Biopharmaceuticals Hangzhou

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., also known as EnitiateBio, is a clinical-stage biotechnology company founded in 2020 and headquartered in Hangzhou, China. The company focuses on the discovery and development of innovative small molecule therapies for autoimmune and inflammatory diseases, with a strong emphasis on dermatology and respiratory conditions. Its lead candidate, QY201, is a dual JAK1/TYK2 inhibitor currently in Phase 3 clinical trials for atopic dermatitis and Phase 2 for prurigo nodularis and vitiligo. E-nitiate's pipeline also includes QY101, a topical PDE4 inhibitor in Phase 2 for psoriasis, and QY211, a topical JAK1/TYK2 inhibitor. The company was co-founded by VivaVision Biotech and an investment fund from Betta Pharmaceuticals, and it maintains strategic partnerships with major Chinese pharmaceutical firms like Joincare for its respiratory programs.